Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 661 to 675 of 888 results for community guidance

  1. Harnessing digital innovation for children's mental health

    Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.

  2. Co-producing research into the views and experiences of people who use services:- What approaches have been shown to work in supporting the co-production of research for the purposes of service improvement with people who use services?

    there are many examples in practice that highlight how individuals and communities can positively shape the way that services are...

  3. Pain management programmes:- Are pain management programmes a clinically and cost-effective intervention for women with endometriosis?

    management programmes promote self-management and are often provided in the community.If found to be effective for endometriosis, pain...

  4. What lay members do

    health or care services. The phrase could also refer to someone from a community affected by the committee's topic area. View lay member...

  5. Lung cancer: diagnosis and management (NG122)

    This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.

  6. Healthy start vitamins: special report on cost effectiveness (ECD5)

    This document describes a special report on the cost effectiveness of moving the Healthy Start vitamin programme from the current targeted offering to a universal offering

  7. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  8. People in eligible groups:- What are the important messages and how should they be tailored and delivered to encourage and sustain flu vaccination uptake in eligible groups?

    know how to tailor and deliver messages, for example, to minority ethnic communities, who may have lower vaccination uptake and also be...

  9. Optical coherence tomography for glaucoma:- What is the effectiveness and cost effectiveness of optical coherence tomography (OCT) for diagnosing and monitoring glaucoma?

    substantially as a result of an ageing population and better detection in the community.For diagnosis and monitoring, patients have an...

  10. Colorectal cancer (NG151)

    This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).

  11. EpiFix for chronic wounds (MIB139)

    NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .

  12. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

  13. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

    Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.

  14. Workplace health: management practices (NG13)

    This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.

  15. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.